Melanocortin agonists (PT-141/bremelanotide, melanotan II) show efficacy for both male erectile dysfunction and female sexual arousal disorder through central MC3R/MC4R activation — the only drug class addressing desire in both sexes.
Key findingMelanocortin agonists (bremelanotide, melanotan II) treat sexual dysfunction in both sexes through central MC3R/MC4R activation: ED in men and HSDD/FS
What the researchers found
Melanocortin agonists (bremelanotide, melanotan II) treat sexual dysfunction in both sexes through central MC3R/MC4R activation: ED in men and HSDD/FSAD in women — the only drug class targeting desire/arousal centrally for both genders.
Why it matters
Relevant for pt-141, melanotan, sexual-health.
How the study worked
review study.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2007.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Melanocortins in the treatment of male and female sexual dysfunction.
Current topics in medicinal chemistry, 7(11), 1137-44
Citation
Shadiack, Annette M; Sharma, Shubh D; Earle, Dennis C; Spana, Carl; Hallam, Trevor J. (2007). Melanocortins in the treatment of male and female sexual dysfunction.. Current topics in medicinal chemistry, 7(11), 1137-44.